Eli Lilly and Company
Why trials sponsored by Eli Lilly and Company stopped, in this sample of ClinicalTrials.gov.
22 stopped trials with a clear reason; 41% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| futility | 9 | 41% |
| funding business | 6 | 27% |
| safety | 3 | 14% |
| regulatory | 1 | 5% |
| logistics pi | 1 | 5% |
| slow accrual | 1 | 5% |
| other | 1 | 5% |
Where it ranks
- #1 of 90 sponsors by share of trials stopped for: futility (41%).
- #4 of 90 sponsors by share of trials stopped for: safety (14%).
Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.
Trials
- A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06901349 · WITHDRAWN · funding business
“Study terminated for strategic business reasons” - A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT06007651 · TERMINATED · other
“Participants were not dosed in Part B as per the protocol.” - A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis
NCT05486208 · TERMINATED · futility
“Study terminated due to lack of efficacy signal in atopic dermatitis participants.” - A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
NCT05123586 · TERMINATED · futility
“Study terminated due to lack of efficacy” - A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes
NCT04667182 · WITHDRAWN · funding business
“Study was withdrawn prior to enrolment due to business decision.” - A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574 · TERMINATED · funding business
“Study terminated due to strategic business decision” - A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT03831191 · TERMINATED · futility
“The study was terminated for lack of efficacy after an interim analysis was performed” - Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
NCT03382912 · TERMINATED · safety
“The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.” - A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
NCT02443337 · TERMINATED · futility
“The study stopped due to lack of efficacy.” - A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
NCT02106364 · WITHDRAWN · regulatory
“Lilly's decision to cancel this trial is due to regulatory uncertainty in China.” - A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
NCT02227784 · TERMINATED · funding business
“Study termination due to program termination.” - A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain
NCT02192190 · TERMINATED · futility
“Interim assessment: Lack of efficacy” - Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
NCT01870284 · WITHDRAWN · logistics pi
“Due to unexpected operational issues outside of Lilly's control the study has been closed” - A Study of Tadalafil for Duchenne Muscular Dystrophy
NCT01865084 · TERMINATED · futility
“The study is being terminated for lack of efficacy” - A Study of Evacetrapib in High-Risk Vascular Disease
NCT01687998 · TERMINATED · futility
“Study termination due to insufficient efficacy.” - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
NCT01687478 · TERMINATED · futility
“Interim assessment: Lack of efficacy” - A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
NCT01316263 · TERMINATED · slow accrual
“Trial terminated strategically due to poor accrual.” - A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
NCT01209832 · TERMINATED · safety
“Terminated based on safety results from another trial” - A Study for Adults With Plaque Psoriasis
NCT01018810 · TERMINATED · funding business
“The trial was terminated for several reasons, including complexities in development of LY2525623, but not because of safety concerns” - A Study of LY2599506 in Patients With Type 2 Diabetes
NCT01024244 · TERMINATED · safety
“Terminated due to nonclinical safety findings” - A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
NCT00845039 · TERMINATED · funding business
“Study terminated early 22Feb2010 with only 4 participants due to business reasons.” - Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
NCT00326911 · TERMINATED · futility
“The planned enrollment was 130 patients and the study was halted prematurely due to lack of efficacy in both arms. Enrolled patients continued treatment.”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.